UNSPSC 51263114: Bunitrolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F2613LO055, chemically known as 2-propanol, 3-(tert-butylamino)-1-(m-cyanophenoxy)- but generally known as bunitrolol, which bears US NIH Compound Identifier 2473. Bunitrolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bunitrolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05978MIG.

UNSPSC 51263114 Bunitrolol is a Commodity code that encompasses pharmaceutical products and related health-supply procurement by state and local agencies. Based on recent solicitation activity, state and local governments are buying naloxone and drug deactivation systems, pharmaceutical benefit management services, and direct-to-manufacturer prescription fulfillment capabilities under this code. The issuing bodies include county health departments (Seminole County, Florida) and state health and human services commissions (Texas Health and Human Services Commission), reflecting a mix of local public health authorities and state-level pharmacy benefit administration.

Recent opportunities show geographic activity in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and wholesalers, targeting self-insured employers and state agencies. The Seminole County procurement requires electronic bid submission through the county e-Procurement Portal with fixed-fee pricing; the Texas RFI is an exploratory information-gathering phase preceding formal competitive solicitation. Both opportunities reflect state and local interest in controlling pharmaceutical costs and improving supply chain efficiency for high-volume or high-need medications.